{"id":8891,"date":"2026-04-28T12:24:05","date_gmt":"2026-04-28T12:24:05","guid":{"rendered":"https:\/\/godshand.link\/ground_post\/who-pharmaceuticals-newsletter-2026-no-1\/"},"modified":"2026-04-28T12:24:05","modified_gmt":"2026-04-28T12:24:05","slug":"who-pharmaceuticals-newsletter-2026-no-1","status":"publish","type":"ground_post","link":"https:\/\/godshand.link\/en_gb\/ground_post\/who-pharmaceuticals-newsletter-2026-no-1\/","title":{"rendered":"WHO pharmaceuticals newsletter: 2026, No. 1"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n
\n \"WHO
\n <\/figure>\n
Download (890.3 kB)<\/span><\/a><\/div><\/div>\n
\n
\n
\n
\n

Overview <\/h3>\n
<\/div>\n
The WHO pharmaceuticals newsletter provides you\u00a0with the latest information on the safety of medicinal\u00a0<\/span>products and regulatory actions taken by authorities\u00a0<\/span>around the world.\u00a0<\/span><\/div>\n
In addition, this edition includes a summary of\u00a0recommendations from the twenty-fourth meeting of the\u00a0<\/span>WHO Advisory Committee on Safety of Medicinal\u00a0<\/span>Products (ACSoMP), November 2025.<\/span><\/div>\n
<\/div>\n
<\/div>\n
<\/span><\/div>\n
<\/div>\n
\n \n <\/div><\/div><\/div>\n
\n
\n
\n
WHO Team<\/div>\n
\n
\nPharmacovigilance (PVG), <\/span>
\n
\nRegulation and Prequalification (RPQ) <\/span>\n <\/div><\/div>\n
\n
Editors<\/div>\n
World Health Organization<\/div><\/div>\n
\n
Number of pages<\/div>\n
23<\/div><\/div>\n
\n
Reference numbers<\/div>\n
\n
ISBN: <\/strong>9789240122345 (electronic version)<\/span><\/div><\/div><\/div>\n
\n
Copyright<\/div>\n


\n
\n
\n
\n
\n <\/a>\n <\/div><\/div><\/div><\/div><\/div><\/div>\n<\/section>\n


\n
Source link <\/a><\/p>","protected":false},"excerpt":{"rendered":"

Download (890.3 kB) Overview The WHO pharmaceuticals newsletter provides you\u00a0with the latest information on the safety of medicinal\u00a0products and regulatory actions taken by authorities\u00a0around the world.\u00a0 In addition, this edition includes a summary of\u00a0recommendations from the twenty-fourth meeting of the\u00a0WHO Advisory Committee on Safety of Medicinal\u00a0Products (ACSoMP), November 2025. WHO Team Pharmacovigilance (PVG), Regulation and Prequalification (RPQ) Editors World Health…<\/p>","protected":false},"author":99035,"featured_media":8892,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","format":"standard","meta":{"give_campaign_id":0,"footnotes":""},"tags":[696,2368],"ground_category":[315,316],"class_list":["post-8891","ground_post","type-ground_post","status-publish","format-standard","has-post-thumbnail","hentry","tag-newsletter","tag-pharmaceuticals","ground_category-2-grounds-tribulation","ground_category-2-1-time-disease"],"fifu_image_url":"https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/a2cf2aa5-489c-4390-b732-86431d386b9e\/content","_links":{"self":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post\/8891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post"}],"about":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/types\/ground_post"}],"author":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/users\/99035"}],"replies":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/comments?post=8891"}],"version-history":[{"count":0,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_post\/8891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/media\/8892"}],"wp:attachment":[{"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/media?parent=8891"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/tags?post=8891"},{"taxonomy":"ground_category","embeddable":true,"href":"https:\/\/godshand.link\/en_gb\/wp-json\/wp\/v2\/ground_category?post=8891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}